Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FCER2 | P06734 | 4/20 | 0.58 |
| ▸ | MMP1 | P03956 | 3/20 | 0.58 |
| ▸ | REN | P00797 | 2/20 | 0.53 |
| ▸ | MME | P08473 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.53 |
| ▸ | MMP3 | P08254 | 2/20 | 0.53 |
| ▸ | MMP7 | P09237 | 1/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10272569 | 0.88 | MMP1 (0.62) | FCER2MMP1MMEMMP2MMP3 | |
| SCHEMBL2873585 | 0.87 | MME (0.62) | MMEMMP2MMP7 | |
| SCHEMBL7302253 | 0.86 | FCER2 (0.61) | FCER2MMP1RENMMEMMP2 | |
| SCHEMBL22300787 | 0.86 | MEN1 (0.59) | MMEMMP2MMP7 | |
| SCHEMBL23870381 | 0.86 | FCER2 (0.61) | FCER2MMP1RENMMEMMP2 | |
| SCHEMBL242142 | 0.85 | FCER2 (0.60) | FCER2MMP1RENMMEMMP2 | |
| SCHEMBL242141 | 0.85 | FCER2 (0.60) | FCER2MMP1RENMMEMMP2 | |
| SCHEMBL17132263 | 0.84 | FCER2 (0.59) | FCER2MMP1RENMMP2MMP3 | |
| SCHEMBL30573682 | 0.84 | FCER2 (0.59) | FCER2MMP1RENMMP2MMP3 | |
| SCHEMBL16023850 | 0.83 | FCER2 (0.52) | FCER2MMP1RENMMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021195183-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN EMBRYONIC ECTODERM DEVELOPMENT ACTIVITY AND TREATING DISEASE | EXO THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |